Live Breaking News & Updates on Directed Organophosphate

Nutra Pharma Corporation: Nutra Pharma Letter to Shareholders
Plantation, Florida (Newsfile Corp. - January 12, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company s Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company s website.
The last year was a challenging one for all businesses but was certainly a very busy year at Nutra Pharma, explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. Regardless of the global pandemic and economic downturn, Nutra Pharma was able to create new opportunities for our products and technologies. This has provided a strong platform for real growth in 2021, he continued. I wanted to take this opportunity to ....

United States , Coral Springs , Nina Goldstein , Dale Vanderputten , Nutra Pharma , Nutra Pharma Corp , Nutra Pharma Corporation , Nutra Pharma The Company , Florida Newsfile Corp , Defense Threat Reduction Agency , Pharma Corporation , Pet Pain Away , Equine Pain Away , Multiple Sclerosis , Human Immunodeficiency Virus , Chief Executive Officer , Rikj Deitsch , Tech Watch , Nicotinic Acetylcholine Receptor , Directed Organophosphate , Chronic Pain Relief , Walmart Marketplace , Shareholder Letter , ஒன்றுபட்டது மாநிலங்களில் , பவளம் நீரூற்றுகள் , நினா கோல்ட்ஸ்டைன் ,